The role of the novel adipocyte-derived hormone adiponectin in human disease.

By J. Díez, P. Iglesias. European Journal of Endocrinology, 2003

1,185 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Adiponectin, a Therapeutic Target for Obesity, Diabetes, and Endothelial Dysfunction (2017, methodology): “Adiponectin (also known as Acrp30 [2], AdipoQ [11], GBP-28 [12], and apM1 [3]) is a 244-amino acid protein secreted mainly by the adipose tissue.”
Obesity and Its Metabolic Complications: The Role of Adipokines and the Relationship between Obesity, Inflammation, Insulin Resistance, Dyslipidemia and Nonalcoholic Fatty Liver Disease (2014, background): “Levels of adiponectin are low in obese subjects, and treatment with adiponectin increases insulin sensitivity in animal models [160,161].”
Mechanisms of obesity-associated insulin resistance: many choices on the menu. (2007, background): “Adiponectin levels are low in obesity, and administration of adiponectin improves insulin resistance in animal models (Berg et al. 2001; Kubota et al. 2002; Diez and Iglesias 2003).”
Adipokinetic hormone functions that are not associated with insect flight (2008, background): “Adiponectin increases insulin sensitivity by increasing fat oxidation and thereby reduces the intracellular triglyceride content of liver and muscle ( Diez & Iglesias, 2003 ).”